In TNBC, it has been suggested that AR activation alters the tumor microenvironment, hence suppressing the antitumor response and upregulating the secretion of the epidermal growth factor receptor (EGFR) ligand amphiregulin (AREG), both stimulating tumor growth and progression. The gene discussed is AR; the disease is neoplasm.